Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Neogen Corporation, Tandem Diabetes Care or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Neogen Corporation, Tandem Diabetes Care and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Neogen Corporation, Tandem Diabetes Care and Inc.

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Latest Health Care Equipment & Supplies and Neogen Corporation, Tandem Diabetes Care, Inc. Stock News

As of September 4, 2026, Neogen Corporation had a $2.6 billion market capitalization, compared to the Health Care Equipment & Supplies median of $423.0 million. Neogen Corporation’s stock is up 70.6% in 2026, up 3.2% in the previous five trading days and up 106.1% in the past year.

Currently, Neogen Corporation does not have a price-earnings ratio. Neogen Corporation’s trailing 12-month revenue is $870.4 million with a -0.9% net profit margin. Year-over-year quarterly sales growth most recently was -0.1%. Analysts expect adjusted earnings to reach $0.310 per share for the current fiscal year. Neogen Corporation does not currently pay a dividend.

As of September 4, 2026, Tandem Diabetes Care, Inc. had a $1.4 billion market cap, putting it in the 49th percentile of all stocks. Tandem Diabetes Care, Inc.’s stock is down 7.6% in 2026, down 7.8% in the previous five trading days and up 60.61% in the past year.

Currently, Tandem Diabetes Care, Inc. does not have a price-earnings ratio. Tandem Diabetes Care, Inc.’s trailing 12-month revenue is $1.0 billion with a -6.1% net profit margin. Year-over-year quarterly sales growth most recently was 5.8%. Analysts expect adjusted earnings to reach $-0.667 per share for the current fiscal year. Tandem Diabetes Care, Inc. does not currently pay a dividend.

How We Compare Neogen Corporation, Tandem Diabetes Care and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Neogen Corporation, Tandem Diabetes Care and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Neogen Corporation, Tandem Diabetes Care and Inc. Growth Grades

Company	Ticker	Growth
Neogen Corporation	NEOG	B
Tandem Diabetes Care, Inc.	TNDM	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Neogen Corporation has a Growth Score of 63, which is Strong. Tandem Diabetes Care, Inc. has a Growth Score of 45, which is Average.

The Growth Grade Winner: Neogen Corporation

As you can clearly see from the Growth Grade breakdown above, Neogen Corporation has a more attractive growth grade than Tandem Diabetes Care, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Neogen Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Neogen Corporation, Tandem Diabetes Care and Inc.’s Momentum Grades

Company	Ticker	Momentum
Neogen Corporation	NEOG	A
Tandem Diabetes Care, Inc.	TNDM	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Neogen Corporation has a Momentum Score of 92, which is Very Strong. Tandem Diabetes Care, Inc. has a Momentum Score of 80, which is Strong.

The Momentum Grade Winner: Neogen Corporation

As you can clearly see from the Momentum Grade breakdown above, Neogen Corporation is considered to have stronger momentum compared to Tandem Diabetes Care, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Neogen Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Neogen Corporation, Tandem Diabetes Care and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Neogen Corporation	NEOG	C
Tandem Diabetes Care, Inc.	TNDM	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Neogen Corporation has a Earnings Estimate Score of 58, which is Neutral. Tandem Diabetes Care, Inc. has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Grade Winner: Tandem Diabetes Care, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Tandem Diabetes Care, Inc. has a better Earnings Estimate Revisions Grade than Neogen Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Tandem Diabetes Care, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Neogen Corporation, Tandem Diabetes Care and Inc. Grades

In addition to Growth, Momentum and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Neogen Corporation, Tandem Diabetes Care and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Neogen Corporation, Tandem Diabetes Care or Inc. Stock?

Overall, Neogen Corporation stock has a Growth Score of 63, Momentum Score of 92 and Estimate Revisions Score of 58.

Tandem Diabetes Care, Inc. stock has a Growth Score of 45, Momentum Score of 80 and Estimate Revisions Score of 63.

Comparing Neogen Corporation, Tandem Diabetes Care and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.